Heterodimeric proteins

A heterodimer, antibody technology, applied in the direction of immunoglobulin, hybrid immunoglobulin, serum immunoglobulin, etc., can solve the problem of non-specific activation, toxicity and so on

Active Publication Date: 2016-03-02
XENCOR INC
View PDF98 Cites 9 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] Thus, while bispecific antibodies generated from antibody fragments encounter biophysical and pharmacokinetic hurdles, those constructs with full-length antibody-like formats have the disadvantage that they are multivalent in the absence of a primary target antigen. Engage common target antigens efficiently, leading to non-specific activation and potential toxicity

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Heterodimeric proteins
  • Heterodimeric proteins
  • Heterodimeric proteins

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0375] Example 1. Design of unnatural charge displacements to reduce pI

[0376] The antibody constant chain is modified with a lower pi by engineered substitutions in the constant domain. A reduced pi can be engineered by substituting a basic amino acid (K or R) for an acidic amino acid (D or E), which results in a maximal decrease in pi. Mutations from basic to neutral amino acids and from neutral to acidic amino acids will also result in a decrease in pi. A list of amino acid pK values ​​can be found in Table 1 of Bjellqvist et al., 1994, Electrophoresis 15:529-539.

[0377] We chose to develop substitutions in the CH1 (Cγ1) and CL (Ckappa or CK) regions of the antibody (sequences shown in Figure 13 middle) because, unlike the Fc region, they do not interact with natural ligands that affect the pharmacological properties of the antibody. In deciding which position to mutate, consideration is given to the surrounding environment and the number of contact points of the WT...

Embodiment 2

[0383] Embodiment 2. Transformation method of constant region pI transformation

[0384] Reduction of the pi of a protein or antibody can be performed in a number of ways. At the highest basic level, residues with high pKa (lysine, arginine and to some extent histidine) are replaced by neutral or negatively charged residues, and / or neutral residues are replaced by low pKa residues (aspartic acid and glutamic acid) were replaced. The particular substitution may depend on many factors, including position in structure, position in function, and immunogenicity.

[0385] Because immunogenicity is an issue, some effort can be made to minimize the risk that substitutions that lower the pI will cause immunogenicity. One way to reduce risk is to minimize the mutational load of the variant, ie, reduce the pi with the smallest number of mutations. Charge exchange mutations, in which K, R, or H are replaced by D or E, have the greatest effect on reducing pi, so these substitutions are ...

Embodiment 3

[0389] Example 3. Isotype light chain constant region variants

[0390] The homology between CK and Cλ is not as high as that between IgG subclasses, however the sequence and structural homology that exists is still used to guide substitutions to form the isotype low-pi light chain constant region. exist Figure 56 In , positions with residues contributing to higher pi (K, R and H) or lower pi (D and E) are highlighted in bold. Gray indicates lysine, arginine and histidine that can be replaced, preferably with aspartic acid or glutamic acid, to lower the isoelectric point. These variants, alone or in combination, can be combined independently and optionally with all other heavy chain variants in the backbone having at least one light chain.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

In one aspect, the present invention provides heterodimeric antibodies comprising a first monomer comprising a first heavy chain constant domain comprising a first variant Fc domain and a first antigen binding domain and a second monomer comprising a second heavy chain constant domain comprising a second variant Fc domain and a second antigen binding domain. In an additional aspect the heterodimeric antibody comprises a first monomer comprising a heavy chain comprising a first Fc domain and a single chain Fv region (scFv) that binds a first antigen, wherein the scFv comprises a charged scFv linker. The heterodimeric antibody further comprises a second monomer comprising a first heavy chain comprising a second Fc domain and a first variable heavy chain and a first light chain.

Description

[0001] priority [0002] This application is based on International Patent Application No. PCT / US14 / 11549, filed January 14, 2014, U.S. Patent Application No. 14 / 155,334, filed January 14, 2014, 14 / 205,248 and continuation-in-part of 14 / 207,489 filed March 12, 2014. Additionally, this application claims U.S. Patent Application Nos. 61 / 818,513, filed May 1, 2013, 61 / 818,344, filed May 1, 2013, 61 / 794,896, filed March 15, 2013, 61 / 818,401 filed May 1, 61 / 913,879 filed December 9, 2013, 61 / 913,832 filed December 9, 2013, 61 / 938,095 filed February 10, 2014 and Priority of 61 / 913,870 filed December 9, 2013, all of which are specifically incorporated by reference in their entirety, particularly for all figures and legends disclosed herein, and for the amino acid variations disclosed herein. body. Background of the invention [0003] Antibody-based therapies have been successfully used to treat a variety of diseases, including cancer and autoimmune / inflammatory disorders. There ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C07K16/06C07K16/28C07K16/46
CPCC07K16/28A61P37/02C07K1/18C07K16/2809C07K16/2896A61K2039/505C07K2317/31C07K2317/622C07K16/468C07K2317/64C07K2317/94C07K16/065C07K16/2803C07K2317/60C07K2317/71C07K2317/72C07K16/00C07K2317/526C07K16/18C07K2317/55
Inventor G·摩尔J·戴斯扎拉斯R·拉施德M·J·伯内特
Owner XENCOR INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap